fbpx
QQQ
+ 7.05
312.29
+ 2.21%
DIA
+ 4.00
336.23
+ 1.18%
SPY
+ 6.32
403.85
+ 1.54%
TLT
+ 1.27
134.54
+ 0.94%
GLD
+ 1.54
169.61
+ 0.9%

Organigram Reports Q2 Results: What Cannabis Stock Investors Need To Know

April 13, 2021 11:42 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
Organigram Reports Q2 Results: What Cannabis Stock Investors Need To Know

Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI) reported Tuesday that gross revenue decreased by 29% year-over-year to roughly CA$19.3 million ($15.4 million) in the second quarter of fiscal 2021.

Net revenue also declined over the same period, from CA$23.2 million to CA$14.6 million, the Moncton, New Brunswick-based company said in a statement. 

The second-quarter results were "challenged by industry dynamics, COVID-19 and staffing limitations at our facility," CEO Greg Engel said in a statement. 

Yet "there are excellent prospects ahead for the industry, Organigram and our shareholders," he added.

Organigram Financial Highlights

  • The second-quarter gross margin came in negative, at CA$17.2 million, representing a year-over-year decrease of 252% from the positive CA$11.3 million reported in the same quarter last year.
  • The net loss amounted to CA$66.4 million, up from CA$6.8 million in the corresponding quarter of 2020. 
  • Adjusted EBITDA (a non-IFRS financial measure) was a negative CA$8.6 million, compared to a CA$59,000 loss in the second quarter of 2020.
  • Selling, general and administrative expenses, excluding non-cash share-based compensation, were CA$11.1 million for the quarter, compared to some CA$14 million in the same period last year.

Organigram anticipates third-quarter revenue to exceed second-quarter results and said it's "improving demand fulfillment with increased staffing."

Management also expects to boost revenue growth through the enhanced production of soft chews and other confectionery products from its Winnipeg Edibles & Infusions facility.

Recent Organigram Operational Milestones

Last week, Organigram purchased The Edibles & Infusions Corp. (a soft chew manufacturer co-founded by AgraFlora Organics International Inc. (OTCQX: AGRA) and Cavalier Candies CEO James Fletcher) for CA$22 million.

It also introduced two new recreational product lines, dubbed Indi and Edison Cannabis Co., in March, on the heels of announcing a collaboration with British American Tobacco PLC (NYSE:BTI).

The tobacco giant opted to buy some 58.3 million shares of Organigram's subsidiary at CA$3.792 each, representing a 19.9% equity interest.

Shares of Organigram traded down by more than 0.5% at the time of the writing of this article.

Photo by Roberto Valdivia on Unsplash.

Más de Organigram en Español en El Planteo.


Related Articles

Video: Cannabis Investing, Stock Picks With C3 Fund's Josh Kincaid, Vice Ventures' Catharine Dockery

With cannabis legalization poised to happen on a federal level sooner than later and continued growth of the cannabis industry, marijuana stocks are making an impact within the sin-stock market.  read more

The Week In Cannabis: Big Tobacco, MSO Goes To Europe, Mexico, DC, And More

This was a week of big news for the cannabis industry. read more

Why The British American Tobacco Investment In OrganiGram Is Important

OrganiGram Holdings Inc’s (NASDAQ: OGI) stock is likely to re-rate following the investment by a subsidiary of British American Tobacco PLC (NYSE: BTI), according to Cantor Fitzgerald. read more

BAT Invests $175.7M In Organigram To Work On Next-Gen CBD Products

Tobacco giant British American Tobacco PLC (NYSE: BTI) opted to invest CA$221 million ($175.7 million) in OrganiGram Holdings Inc (NASDAQ: OGI) read more